6660 — AIM Vaccine Co Income Statement
0.000.00%
- HK$3.21bn
- HK$5.04bn
- CNY1.17bn
Annual income statement for AIM Vaccine Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,570 | 1,264 | 1,187 | 1,285 | 1,166 |
| Cost of Revenue | |||||
| Gross Profit | 1,295 | 1,028 | 901 | 954 | 760 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,166 | 1,673 | 3,414 | 1,515 | 1,874 |
| Operating Profit | -596 | -408 | -2,227 | -230 | -709 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -607 | -434 | -2,271 | -291 | -767 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -676 | -231 | -1,950 | -278 | -744 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -693 | -320 | -1,301 | -277 | -675 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -693 | -320 | -1,301 | -277 | -675 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.571 | -0.223 | -0.12 | -0.211 | -0.272 |